- Company
- Dong-A ST has received the right of DA-4501 from AbbVie
- by An, Kyung-Jin Jul 13, 2021 11:08pm
- Dong-A ST has received the right of MerTK inhibitor from AbbVie for the first time in five years. Dong-A ST has terminated two large technology export contracts with global pharmaceutical companies. Dong-A ST plans to review new possibilities based on joint research data that has been conducted for the past five years. Starting with biosim
- Company
- Venclexta combo in the spotlight as a new lymphoma Tx option
- by Jul 13, 2021 05:59am
- The treatment landscape for elderly patients with acute myeloid leukemia (AML), which has a 5-year relative survival rate of less than 10%, is changing with the introduction of a new drug that addresses the unmet needs and improves survival rate. AML is one of the most common types of leukemia in adults with a high unmet need in patients
- Company
- “Reimburse Vyndamax, the only hope for amyloidosis”
- by Eo, Yun-Ho Jul 13, 2021 05:59am
- The hATTR Patients Association came forward to call for the reimbursement approval of ‘Vyndamax’ The patient group recently delivered a ‘Statement for the insurance benefit of Vyndamax' to the Ministry of Health and Welfare and the National Health Insurance Services. The move arose among patients with the reimbursement discussions being
- Company
- Takeda's innovation in Korea
- by Eo, Yun-Ho Jul 12, 2021 06:20pm
- Takeda Korea, which sold off OTC division & DM division, which was the company's symbol. On the occasion of the 10th anniversary of the corporation's launch, constraints have once again confirmed their commitment to pursuing innovation. Marking the 240th anniversary of Takeda Pharmaceutical's headquarters and Korea Takeda's 10th Annivers
- Company
- Byfavo can be prescribed in general hospitals
- by Eo, Yun-Ho Jul 12, 2021 06:19pm
- The anesthetic drug Byfavo can be prescribed at a general hospital. According to related industries, Hana Pharm's Byfavo (Remimazolam Besylate) passed DC of Big 5 general hospitals, including Seoul National University Hospital and Asan Medical Center, and will also be able to be prescribed it at major advanced general hospitals this month.
- Company
- Huons has secured domestic rights to Sputnik Light
- by Lee, Seok-Jun Jul 11, 2021 07:03pm
- Huons said on the 7th that it has secured exclusive rights to domestic licenses and sales of Russia's one-shot vaccine Sputnik Light. Sputnik Light will be produced from Huons Global Consortium starting from second half of this year. It was developed by Gamaleya Research Institute of Epidemiology and Microbiology. It is a one-shot vacci
- Company
- Researchers find COVID-19 Txs more effective than remdesivir
- by Kim, Jin-Gu Jul 9, 2021 05:56am
- A Korean research team of the Korea Advanced Institute of Science and Technology (KAIST) discovered new drug candidates for the treatment of COVID-19. Some of the candidates are expected to have a better effect than the currently approved remdesivir (product name: Veklury). On the 8th, the joint research team of Sang-yup Lee, Distinguished Pr
- Company
- Jeil's anti-cancer drug business is doing well
- by Nho, Byung Chul Jul 8, 2021 05:59am
- It is noteworthy that Jeil is investing in expanding the lineup of anticancer drugs and research and development in related fields. Jeil, who entered his 33rd year of anti-cancer drug business, has a strategic relationship with Kyowa Kirin and Taiho in Japan and is making efforts to distribute original anti-cancer drugs. When the new
- Company
- Chong Kun Dang loses 1st substance patient suit on ‘Xarelto
- by Kim, Jin-Gu Jul 8, 2021 05:58am
- Chong Kun Dang has lost its first trial targeting the substance patent of Bayer’s new oral anticoagulant (NOAC) ‘Xarelto(rivaroxaban).’ Whether Chong Kun Dang will modify its strategy to preoccupy the market through a release of its generic before substance patent expiry due to this ruling is gaining attention. On the 6th, the Intel
- Company
- GC Pharma, the most likely company to produce Covivak
- by Nho, Byung Chul Jul 8, 2021 05:58am
- Chumakov Institute recently visited Andong Animal Cell Verification Support Center. Russia's Covivak is likely to be produced in domestic CMOs. According to industries, MPC, which is a South Korean corporation to introduce Covivak, recently signed a contract with Pharm Bio-tech, a Russian company that has rights to produce and publish in
